We will hold individual interviews of HLBS patients, including a range of racial, ethnic, and socioeconomic perspectives, to discuss current and future Artificial Intelligence/Big Data technologies. Participants will be recruited from University of Arizona affiliated clinical practices or online, offering $25 each for participation in 60-minute discussions, either by phone or video conference
The purpose of this study is to determine if treatment with omecamtiv mecarbil/AMG 423 when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in subjects with chronic HFrEF.
We propose to 1) assess the feasibility and acceptability of a prescribed beverage intervention in 50 obese Hispanic adults ages 18-64 years over 6 weeks; 2) assess preliminary effects of the beverage intervention on cholesterol and triglyceride levels as well as other markers of health such as blood pressure, glucose and markers of inflammation.
Peripheral arterial disease (PAD) affects millions of patients in the United States and has been a key focus of research for our group at the Southern Arizona Limb Salvage Alliance (SALSA). PAD is caused by genetic factors as well as hyperlipidemia, smoking, hypertension and diabetes. Care for patients with PAD focuses on medical optimization, mechanical optimization, wound care and surgical revascularization, without which patients have a large degree of impairment resulting from chronic wounds and amputations.
Torsades de pointes (TdP) is a rare life threatening heart arrhythmia. It occurs in individuals with genetic mutations in genes that control the expression of ion channel proteins in the heart and is a frequent cause of sudden death in these individuals. TdP also occurs as a complication of drugs that prolong a cardiac timing interval by blockade of potassium channels. This list of drugs includes the antibiotics erythromycin, azithromycin, clarithromycin, levofloxacin and ciprofloxacin.
The assembled collection of biospecimens and the associated clinical/genetic data will be the foundation for experiments with the statistical power to provide the insights from the state of the art technologies in genomics and proteomics. If the collection doesn’t exist, the insights available from the new technologies cannot find their way to PAH research. While generating a biobank is not a new idea, what is new is the inventory and tracking system, the software, specimen extraction, and communication with users to implement the Best Practices applied to PAH.